Serena Jingchuan Guo

Serena Jingchuan Guo, M.D., Ph.D.

Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6533
Business Email: guoj1@ufl.edu

About Serena Jingchuan Guo

Serena Guo is Assistant Professor in the Department of Pharmaceutical Outcomes and Policy at the University of Florida (UF) College of Pharmacy. She received her MD from Peking University in Beijing, China and her PhD in epidemiology from the University of Pittsburgh. After a one-year postdoctoral fellowship in the Center for Pharmaceutical Policy and Prescribing also at the University of Pittsburgh, in December 2020, Dr. Guo joined the faculty of UF. Dr. Guo has published nearly 50 peer-reviewed manuscripts. Several articles have been published in top-tier journals, including Diabetes Care, Lancet and BMJ, and featured in media outlets, including Washington Post, NPR, and CNN.

Dr. Guo conducts epidemiologic and health services research focusing on cardiovascular health and diabetes. Her research draws on large healthcare databases and advanced analytics (e.g., machine learning and causal mediation analysis) to evaluate: 1) geographic and racial and ethnic inequities in treatment use and clinical outcomes, 2) the effects of potentially modifiable social determinants of health (e.g., neighborhood-level social and built environment and individuals’ social-behavioral factors), and 3) fairness and bias in machine learning predictions across racial and ethnic groups.

Related Links:

Teaching Profile

Courses Taught
2021-2023
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2022
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2022
PHA5878C Pt Care 3: Cv and Pulm
2022
PHA6938 Research Seminar

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0001-9799-2592

Publications

2022
Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis
Journal of the American Pharmacists Association. 62(6):1816-1822.e2 [DOI] 10.1016/j.japh.2022.07.003.
2022
Are novel glucose‐lowering agents’ cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment
Diabetes, Obesity and Metabolism. 24(1):154-159 [DOI] 10.1111/dom.14540.
2022
Changes in predicted opioid overdose risk over time in a state Medicaid program: a group‐based trajectory modeling analysis
Addiction. 117(8):2254-2263 [DOI] 10.1111/add.15878.
2022
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism. [DOI] 10.1111/dom.14894.
2022
Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials
Diabetes Care. 45(4):1007-1012 [DOI] 10.2337/dc21-1722.
2022
Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system–based cross-sectional study
PLOS Medicine. 19(7) [DOI] 10.1371/journal.pmed.1004069. [PMID] 35901171.
2022
Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group‐based multi‐trajectory models
Addiction. 117(7):1982-1997 [DOI] 10.1111/add.15857.
2022
Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis.
American heart journal plus : cardiology research and practice. 13 [DOI] 10.1016/j.ahjo.2022.100096. [PMID] 35136865.
2022
Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach.
Frontiers in pharmacology. 13 [DOI] 10.3389/fphar.2022.834743. [PMID] 35359843.
2022
Income disparities in driving distance to health care infrastructure in the United States: a geographic information systems analysis
BMC Research Notes. 15(1) [DOI] 10.1186/s13104-022-06117-w. [PMID] 35761413.
2022
Newer glucose‐lowering drugs and risk of dementia: A meta‐analysis of cardiovascular outcome trials
Journal of the American Geriatrics Society. 70(9):2719-2722 [DOI] 10.1111/jgs.17895. [PMID] 35612586.
2022
Simulating Colorectal Cancer Trials Using Real-World Data
JCO Clinical Cancer Informatics. (6) [DOI] 10.1200/cci.21.00195.
2021
COVID-19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data.
Journal of the American Heart Association. 10(24) [DOI] 10.1161/JAHA.121.023235. [PMID] 34913359.
2021
Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage.
Journal of managed care & specialty pharmacy. 27(10):1500-1502 [DOI] 10.18553/jmcp.2021.27.10.1500. [PMID] 34595947.
2021
Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries
American Journal of Cardiovascular Drugs. [DOI] 10.1007/s40256-021-00475-9. [PMID] 33768423.
2021
Newer drug treatments for type 2 diabetes.
BMJ (Clinical research ed.). 373 [DOI] 10.1136/bmj.n1171. [PMID] 33975861.
2021
Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose.
Journal of general internal medicine. 36(4):908-915 [DOI] 10.1007/s11606-020-06405-w. [PMID] 33481168.
2021
Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation.
Journal of managed care & specialty pharmacy. 27(12):1672-1679 [DOI] 10.18553/jmcp.2021.27.12.1672. [PMID] 34818086.
2021
Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation.
Frontiers in public health. 9 [DOI] 10.3389/fpubh.2021.780185. [PMID] 34805085.
2021
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Lancet (London, England). 396(10267):2019-2082 [DOI] 10.1016/S0140-6736(20)32374-6. [PMID] 33189186.
2021
Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data.
Pharmacoepidemiology and drug safety. 30(5):644-651 [DOI] 10.1002/pds.5206. [PMID] 33606340.
2020
Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas.
The American journal of cardiology. 130:64-69 [DOI] 10.1016/j.amjcard.2020.06.015. [PMID] 32680675.
2020
Costs and outcomes of “intermediate” vs “minimal” care for youth-onset type 1 diabetes in six countries.
Pediatric diabetes. 21(4):628-636 [DOI] 10.1111/pedi.12988. [PMID] 31970828.
2020
Mediation analysis for estimating cardioprotection of longitudinal RAS inhibition beyond lowering blood pressure and albuminuria in type 1 diabetes.
Annals of epidemiology. 41:7-13.e1 [DOI] 10.1016/j.annepidem.2019.12.004. [PMID] 31928894.
2020
Occupational Patterns of Opioid-Related Overdose Deaths Among Arizona Medicaid Enrollees, 2008-2017.
Journal of general internal medicine. 35(7):2210-2213 [DOI] 10.1007/s11606-020-05684-7. [PMID] 32043261.
2019
Excess mortality and cardiovascular disease risk in type 1 diabetes.
Lancet (London, England). 393(10175) [DOI] 10.1016/S0140-6736(18)33047-2. [PMID] 30860050.
2019
Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen.
Journal of the American Society of Nephrology : JASN. 30(10):2000-2016 [DOI] 10.1681/ASN.2019030218.
2019
Greater progression of coronary artery calcification is associated with clinically relevant cognitive impairment in type 1 diabetes.
Atherosclerosis. 280:58-65 [DOI] 10.1016/j.atherosclerosis.2018.11.003. [PMID] 30471556.
2019
Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes.
Diabetes care. 42(9):1692-1699 [DOI] 10.2337/dc19-0480. [PMID] 31248910.
2019
Prognostic Significance of Pulse Pressure and Other Blood Pressure Components for Coronary Artery Disease in Type 1 Diabetes.
American journal of hypertension. 32(11):1075-1081 [DOI] 10.1093/ajh/hpz099. [PMID] 31214692.
2019
Serum long-chain n-3 polyunsaturated fatty acids and aortic calcification in middle-aged men: The population-based cross-sectional ERA-JUMP study.
Nutrition, metabolism, and cardiovascular diseases : NMCD. 29(8):837-846 [DOI] 10.1016/j.numecd.2019.04.011. [PMID] 31151884.
2019
The role of coronary artery calcification testing in incident coronary artery disease risk prediction in type 1 diabetes.
Diabetologia. 62(2):259-268 [DOI] 10.1007/s00125-018-4764-2. [PMID] 30426170.
2018
Association of alcohol consumption and aortic calcification in healthy men aged 40-49 years for the ERA JUMP Study.
Atherosclerosis. 268:84-91 [DOI] 10.1016/j.atherosclerosis.2017.11.017. [PMID] 29195109.
2018
Data on alcohol consumption and coronary artery calcification among asymptomatic middle-aged men for the ERA-JUMP study.
Data in brief. 17:1091-1098 [DOI] 10.1016/j.dib.2018.02.032. [PMID] 29876466.
2018
Left ventricular systolic dysfunction predicts long-term major microvascular complication outcomes in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood onset diabetes.
Journal of diabetes and its complications. 32(3):298-304 [DOI] 10.1016/j.jdiacomp.2017.12.004. [PMID] 29366734.
2017
Increased Aortic Calcification Is Associated With Arterial Stiffness Progression in Multiethnic Middle-Aged Men.
Hypertension (Dallas, Tex. : 1979). 69(1):102-108 [PMID] 27821619.
2017
Reply.
Journal of hypertension. 35(6):1326-1327 [DOI] 10.1097/HJH.0000000000001342. [PMID] 28441260.
2017
The role of initial and longitudinal change in blood pressure on progression of arterial stiffness among multiethnic middle-aged men.
Journal of hypertension. 35(1):111-117 [PMID] 27775956.
2016
Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
British journal of clinical pharmacology. 82(2):352-61 [DOI] 10.1111/bcp.12950. [PMID] 27038001.

Grants

Oct 2022 ACTIVE
VA IPA Year 1 Jingchuan Guo
Role: Principal Investigator
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2022 ACTIVE
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2022 ACTIVE
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2022 ACTIVE
Social Determinants Underlying Disparities in Heart Failure Treatment and Outcomes
Role: Principal Investigator
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Dec 2021 ACTIVE
The External Exposome and COVID-19 Severity and Mortality
Role: Co-Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL via NATL INST OF HLTH NIEHS
Sep 2021 – Sep 2022
Disparities in Peripheral Arterial Disease Diagnosis and Treatment in Socioeconomically Disadvantaged Regions of Florida
Role: Other
Funding: AMER COL OF CARDIOLOGY
Jul 2021 ACTIVE
Pandemic Disruptions of Atrial Fibrillation Care
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN DIEGO via NATL INST OF HLTH NHLBI
Jul 2019 ACTIVE
OoR Matching Support for CTSI
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS

Contact Details

Phones:
Business:
(352) 273-6533
Emails:
Business:
guoj1@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
1225 Center Drive, HPNP 2338
Gainesville FL 32610